WALTHAM, Mass., Oct. 11 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. , the world leader in serving science, today announced its plan to construct an $11 million, state-of-the-art BioCenter for the manufacture of single-use bioprocess containers (BPCs) and related products at the site of its existing bioprocess production business unit in Logan, Utah.
The BioCenter investment is a response to the increasing demand for disposable bioprocessing technology among customers in the life-sciences research, biotechnology and pharmaceutical industries. Bioprocess containers serve cell-culture applications as well as the production of protein-based drugs, and are used in mixing, storage and transportation of bioprocessing fluids and for bioreactors (used to grow cells, proteins and other biochemically active substances). Single-use bioprocessing components eliminate the risk of batch-to-batch cross contamination and significantly reduce startup costs for customers.
“We are excited about the expanded capabilities that our BioCenter will provide,” said Marc N. Casper, executive vice president of Thermo Fisher Scientific. “The market outlook for the bioprocessing industry continues to be very bright as there are thousands of biotech products under development. This investment will allow us to better meet the needs of our customers as they work toward new therapies for treating disease and improving health.”
The 37,000-square-foot facility is expected to be complete by the fall of 2008. It is the first of a three-phase construction plan that will create a 94,000-square-foot BioCenter over the next four years, replacing and expanding an older BPC operation in Logan. The new operation will include an administration building, sera and liquid-media processing facility, powdered- media facility, warehouse and the existing BPC facility. The initial project is expected to create 75 new jobs, both in production and management functions.
Products to be manufactured in the new facility include the Thermo Scientific HyClone BPC line -- ranging from simple bioprocess containers, to complex bioprocessing systems and custom-designed units for a variety of applications. This offering includes sterile fluid-handling bags, bag manifold systems, tank liners, chambers, biopharmaceutical tubing and other accessories, as well as the recently introduced Thermo Scientific HyClone Single-Use Bioreactor (S.U.B.) and Single-Use Mixer (S.U.M.).
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com.
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward- looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investors” section of our Website under the heading “SEC Filings.” We also may make forward-looking statements about the benefits of the merger of Thermo Electron and Fisher Scientific, including statements about future financial and operating results, the new company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the risk that the businesses will not be integrated successfully; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers’ capital spending policies and government funding policies; realization of potential future savings from new productivity initiatives; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations; the effect of exchange rate fluctuations on international operations; the effect of laws and regulations governing government contracts; the effect of competing with certain of our customers and suppliers; and the effect of rapid changes in the healthcare industry. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
lori.gorski@thermofisher.comken.apicerno@thermofisher.comhttp://www.thermofisher.com/hyclone
CONTACT: Media: Lori Gorski, Public Relations Manager, +1-781-622-1242,
lori.gorski@thermofisher.com, or Investors: Ken Apicerno, +1-781-622-1111,
ken.apicerno@thermofisher.com, both of Thermo Fisher Scientific
Web site: http://www.thermofisher.com/
Company News On-Call: http://www.prnewswire.com/comp/877850.html /
